Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.78M Hold
8,169
0.57% 25
2025
Q4
$1.87M Hold
8,169
0.51% 27
2025
Q3
$1.89M Hold
8,169
0.47% 27
2025
Q2
$1.52M Hold
8,169
0.3% 29
2025
Q1
$1.71M Buy
8,169
+23
+0.3% +$4.47K 0.33% 24
2024
Q4
$1.45M Hold
8,146
0.28% 26
2024
Q3
$1.61M Hold
8,146
0.31% 25
2024
Q2
$1.4M Hold
8,146
0.26% 26
2024
Q1
$1.48M Sell
8,146
-3
-0% -$517 0.28% 26
2023
Q4
$1.26M Buy
8,149
+3
+0% +$437 0.27% 27
2023
Q3
$1.21M Hold
8,146
0.26% 28
2023
Q2
$1.1M Buy
8,146
+500
+7% +$73.3K 0.24% 37
2023
Q1
$1.22M Buy
+7,646
New +$1.17M 0.29% 30

Other funds holding ABBV

Sentry LLC's ABBV Position: Q1 2026 in Review

Sentry LLC held its AbbVie (ABBV) position steady in Q1 2026 at 8,169 shares worth $1.78M. The position accounts for 0.57% of the portfolio, ranked #25.

Sentry LLC first reported a position in ABBV in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.89M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Sentry LLC held 8,169 shares of AbbVie worth $1.78M as of Q1 2026.
  • Sentry LLC left its AbbVie share count unchanged in Q1 2026.
  • AbbVie made up 0.57% of Sentry LLC's portfolio in Q1 2026, its #25 holding.
  • Sentry LLC first reported a position in AbbVie in Q1 2023 and has held it in 13 quarters since.
  • Sentry LLC's AbbVie position peaked at $1.89M in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Sentry LLC's 13F filing for Q1 2026, filed 23 Apr 2026.